14.10.2015 • News

BASF Starts Training Scheme for Refugees

“The influx of hundreds of thousands of refugees is a gigantic challenge for...
“The influx of hundreds of thousands of refugees is a gigantic challenge for Germany, which we can only overcome together,” said Margret Suckale, BASF managing board member with responsibility for overseeing Human Resources. “With the new program, we are making a tangible contribution to the integration of refugees into the labor market,” she said.

BASF has enrolled 50 refugees in its new “Start Integration” qualification scheme for workers needing help to find jobs. The German chemical group said enrollment for the program that started simultaneously with the year’s fourth quarter is limited to those who have good chances of remaining in Germany.

In the first stage of the modular undertaking, BASF said it is – in cooperation with other companies and organizations in the Rhine-Neckar region – assessing the participants’ qualifications toward finding them the right job, traineeship or apprenticeship. The initiative for refugees complements BASF’s existing booster program Anlauf zur Ausbildung, which helps young people especially to add new skills before starting an apprenticeship within its group of companies or partner companies.

“The influx of hundreds of thousands of refugees is a gigantic challenge for Germany, which   we can only overcome together,” said Margret Suckale, BASF managing board member with responsibility for overseeing Human Resources. “With the new program, we are making a tangible contribution to the integration of refugees into the labor market,” she said.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read